Skip to main content

4 Result(s)

within Leslie Oleksowicz Remove this filter

and

  1. No Access

    Article

    A phase II trial of dose-intensive interleukin-2 in metastatic renal cell carcinoma

    Purpose: High-dose bolus interleukin-2 (IL-2) is currently the sole agent approved by the Food and Drug Administration for the treatment of advanced renal cell carcinoma. This phase II study was designed to eval...

    Leslie Oleksowicz, Janice P. Dutcher in Journal of Cancer Research and Clinical Oncology (1999)

  2. No Access

    Article

    Therapeutic effect of cyclosporine A in thrombocytopenia after myeloablative chemotherapy in acute myeloid leukaemia

    Four patients with acute myelogenous leukaemia (AML), who developed isolated thrombocytopenia after anti-leukaemic chemotherapy, were treated with cyclosporine A and showed significantly enhanced platelet reco...

    Yelena Novik, Leslie Oleksowicz, Peter H. Wiernik in Medical Oncology (1997)

  3. No Access

    Article

    Atypical clonal T-cell proliferation in infectious mononucleosis

    An atypical case of infectious mononucleosis characterized by fever, acute tonsillitis, and bilateral cervical adenopathy is reported in a previously healthy young man. Although serology was positive for the E...

    Ummekalsoom R. Malik, Leslie Oleksowicz, Janice P. Dutcher… in Medical Oncology (1996)

  4. No Access

    Chapter

    Interleukin-2 (IL-2) Augments the Expression of Transforming Growth Factor Beta in Patients with Disseminated Cancer

    Interleukin-2 (IL-2), originally discovered in the supernatant of lectin or antigen-stimulated T-cell cultures1-2, possesses a panoply of immunologic effects such as induction of paracrine growth of antigen-stimu...

    Pauli Puolakkainen, Paolo Alberto Paciucci… in Growth Factors, Peptides and Receptors (1993)